-
Article
Open AccessThe Effect of Sodium–Glucose Cotransporter Inhibitors on Renal Function as Adjunctive to Insulin in Adults with Type 1 Diabetes: An Updated Multilevel Meta-analysis of Randomized Controlled Trials
This systematic review aimed to summarize the existing evidence from published randomized controlled trials (RCTs) on the impact of sodium–glucose cotransporter (SGLT) inhibitors on albuminuria levels and rena...
-
Article
Open AccessPotential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?
Semaglutide is a potent glucagon-like peptide 1 receptor agonist for the management of type 2 diabetes mellitus. In addition to this, it has emerging potential clinical implications. First, there is accumulati...
-
Article
Are SGLT-2 inhibitors “the elephant in the room” of non-diabetic glomerulonephritis? Considerations about the background immunosuppressive treatment
-
Article
Circulating follistatin as a novel biomarker of type 2 diabetes mellitus risk
-
Article
Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?
-
Article
Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic plasma cell disorder characterised by a serum M protein level below 3 g/dL, percentage of bone marrow clonal plasma cells below 10%,...
-
Article
Open AccessUse of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The latter is a pandemic that has the potential of develo** into a severe illness manifesting as syste...
-
Article
Open AccessClinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study
Insulin glargine 300 U/mL (Gla-300) is a novel glargine formulation which shows slower and more prolonged absorption following subcutaneous administration in comparison to insulin glargine 100 U/mL. In this pr...
-
Article
Open AccessNew Sub-Phenoty** of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?
Prediabetes is defined as a condition of abnormal glucose metabolism, characterised by plasma glucose above normal range but not as high as required for the diagnosis of diabetes mellitus (DM). It represents a...
